Harmony Biosciences Holdings, Inc. income statement

In fiscal 2025, Harmony Biosciences Holdings, Inc. reported revenue of $868m, up 21.5% on the year before, operating income of $208m (a 24.0% margin) and net income of $159m, or $2.71 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Harmony Biosciences Holdings, Inc.: income statement, annual
Fiscal year	2019Dec 2019	2020Dec 2020	2021Dec 2021	2022Dec 2022	2023Dec 2023	2024Dec 2024	2025Dec 2025	LTMJun 2026
Revenue	6	160	305	438	582	715	868	960
Cost of revenue	2	28	56	83	121	157	198	236
Gross profit	4	132	250	354	461	558	670	724
Research and development	70	19	30	71	76	146	190	221
Selling and marketing	44	56	68	79	97	111	120	125
General and administrative	36	40	64	84	95	110	153	148
Operating income	−146	17	88	120	192	191	208	231
Interest expense	7	29	24	19	24	17	15	13
Income before tax	−152	−37	37	105	173	192	215	241
Income tax	—	—	3	−77	45	46	56	60
Net income	−152	−37	35	181	129	145	159	181
Diluted EPS	−$24.07	−$2.48	$0.58	$2.97	$2.13	$2.51	$2.71	$3.09
Diluted shares (average)	8m	26m	59m	61m	60m	58m	59m	59m
EBITDA	−146	17	88	121	193	191	—	—

US$ millions unless shown otherwise. Fiscal quarters.

Harmony Biosciences Holdings, Inc.: income statement, quarterly
Quarter	2024 Q3Sept 2024	2024 Q4Dec 2024	2025 Q1Mar 2025	2025 Q2Jun 2025	2025 Q3Sept 2025	2025 Q4Dec 2025	2026 Q1Mar 2026	2026 Q2Jun 2026
Revenue	186	201	185	200	239	244	215	261
Cost of revenue	43	54	32	38	60	69	45	63
Gross profit	143	147	153	162	180	175	171	198
Research and development	25	35	35	50	55	50	69	47
Selling and marketing	28	28	31	30	30	29	32	34
General and administrative	29	29	31	34	30	58	33	28
Operating income	62	56	56	48	65	39	37	89
Interest expense	4	4	4	4	4	4	3	3
Income before tax	62	56	57	50	67	41	40	93
Income tax	16	7	12	10	17	18	7	18
Net income	46	49	46	40	51	22	32	75
Diluted EPS	$0.79	$0.85	$0.78	$0.68	$0.87	$0.39	$0.55	$1.28
EBITDA	62	56	56	48	65	—	37	89

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: ANIP vs HRMY AXSM vs HRMY HRMY vs SUPN HRMY vs PBH

More: Pharmaceuticals stocks compared, Health Care sector, rankings of US companies

Figures from Harmony Biosciences Holdings, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Harmony Biosciences Holdings, Inc.